KEQU — Stock Film
STOCK FILMSCENE 1/11KEQU · $34.54
Stock Expert AI presents
KEQU
Kewaunee Scientific Corporation
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Kewaunee Scientific Corporation. What it actually does.

Designs and manufactures laboratory furniture. Provides healthcare furniture solutions. Now — the numbers.

on the stock market since 1980
1,231 employees
$99.1M market value
Revenue last year:
$282M
The net profit left over:
$9.6M
Out of every $100 in sales, $3 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 3%

This is an established company with proven profits.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 14% a year over the last 4 years. Red columns mark years that ended in a loss.

$168.9M
2022
2023
2024
2025
$282M
2026
THE PRICE TAG
MARKET VALUE / ANNUAL PROFIT
10.3×

The market pays 10.3× for every dollar of annual profit — cheap, which is either an opportunity or a warning.

Against companies in its own sector, it looks cheaper than 95% of them.

No analyst target is on record for this company.

What executives did with their own stock over the last 12 months:
15 buy56 sell

Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
65
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
82
very strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
95
very strong

The price looks reasonable next to what the company earns.

GROWTH
70
strong

Clearly above the class average — a step short of the very top.

PRICE MOMENTUM
42
weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 50% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/1
Sales keep climbing

Over the last 4 years, sales grew about 14% a year on average.

1
THE RISKS · 1/3
Executives lean toward selling

Over the last 12 months, executives reported 56 sells against just 15 buys. Not an alarm bell by itself, but a number worth watching.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 42/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
Costs eat into the margin

Costs swallow the gains that sales growth brings in.

FINALE · THE GRADE
B
55 / 100 · MoonshotScore

On our five-subject report card, KEQU sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: KEQU is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film